Dr. Thomas Herzog on the Cautions of Interval Debulking Surgery in Ovarian Cancer

November 25, 2015
Thomas Herzog, MD

Thomas Herzog, MD, on the cautions of interval debulking surgery in ovarian cancer and its difference from neoadjuvant treatment. Herzog said interval debulking surgery entails an initial, maximum surgical effort that is followed up by chemotherapy.

Thomas Herzog, MD, clinical director, University of Cincinnati Cancer Institute, talks about the cautions of interval debulking surgery in ovarian cancer and its difference from neoadjuvant treatment. Herzog said interval debulking surgery entails an initial, maximum surgical effort that is followed up by chemotherapy.

Herzog says two separate studies, one in Europe and the United States, had somewhat contradictory results, with one of showing that interval debulking surgery resulted in better overall survival (OS) and one showing that it resulted in no significant increase of OS.

Herzog also notes the United States study, which results in no improved OS, utilized much more aggressive surgery techniques.